

CFU-f apoptotic cells % (Annexin V kit) obtained from systemically treated old mice with BMP-2 (i.p. 0.5, 1.0 ug/day, 20d)




FIG. 1

Grip test (muscle strength) in systemically treated old mice with BMP-2 (i.p. 0.5, 1.0 ug/day, 20d)

Received 6/29/98; accepted 6/30




FIG. 2

Femoral trabecular bone volume (TBV) in old
mice systemically treated with BMP-2
(i.p. 0.5, 1.0 ug/day, 20d)




FIG. 3

CFU-f ALP (+) % obtained from systemically treated old mice with BMP-2 (i.p. 0.5, 1.0 ug/day, 20d)




FIG. 4

CFU-f BrdU (+) % obtained from systemically treated old mice with BMP-2 (i.p. 0.5, 1.0 ug/day, 20d)




FIG. 5

CFU-f apoptotic cells % (DAPI staining) obtained from systemically treated old mice with BMP-2 (i.p. 0.5, 1.0 ug/day, 20d)




FIG. 6




FIG. 7A




FIG. 7B

CFU-f apoptosis % (PI staining) after Adenoviral infection d.6 (Ad-BMP-2 construct 10pfu/plate)




FIG. 7C

Effect of adenoviral infection on d.6 (Adeno-BMP-2 construct 10pfu/cell on CFU-f (ALP+) area




FIG. 7D

X-ray densitometry in segmental defect




FIG. 8

Relative Fluorescence Density in gap




FIG. 9

Histomorphometrical analysis of gap healing




FIG. 10